Epizyme is a biopharmaceutical company that is creating innovative drugs for major diseases based on important discoveries emerging from the field of epigenetics. The company has developed an enabling and integrated platform that is generating a robust and sustainable drug pipeline of first-in-class inhibitors of histone methyl transferases for targeted cancer therapy.
|Scientist/Sr. Scientist, Lead Discovery||Cambridge, MA, US|
|Senior Director/Executive Director, Lead Discovery||Cambridge, MA, US|